Compounds in this category
Argireline (acetyl hexapeptide-8) is the most marketed compound in this category. It is a synthetic hexapeptide mimicking the N-terminus of SNAP-25, the SNARE protein that botulinum toxin targets. The proposed mechanism is mild inhibition of muscle contraction at the dermal level, producing reduced expression-line depth around the eyes and forehead. Published trials report 17 to 30 percent wrinkle-depth reduction over 28 days of twice-daily topical application. The effect size is smaller than injectable botulinum toxin and does not produce visible muscle paresis. Argireline is sold as a cosmetic ingredient, not a drug.
Matrixyl (palmitoyl pentapeptide-4) and Matrixyl 3000 (palmitoyl tetrapeptide-7 plus palmitoyl tripeptide-1) are positioned as collagen-synthesis modulators. The proposed mechanism involves signaling on fibroblast collagen production, with reported increases in type I and type IV collagen in cell culture and small in vivo studies. Effect sizes in human topical trials are modest. The peptides are typically formulated at 3 to 8 percent concentration in finished products.
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) has the deepest peer-reviewed dermal literature in this category. Loren Pickart's group identified the tripeptide in 1973 and documented its role in dermal repair, wound healing, and copper-dependent enzyme activation. Published topical trials report improvements in skin density, fine-line depth, and pigmentation. The compound is also used in research as an injectable, but the cosmetic literature is topical-only. The FDA regulates GHK-Cu cosmetic products as cosmetics, not drugs.
SNAP-8 (acetyl glutamyl octapeptide-3) is a longer analog of argireline, with similar SNARE-competition mechanism and similar evidence depth. Marketing claims of greater potency are not consistently supported by head-to-head trials.
Syn-Ake (dipeptide diaminobutyroyl benzylamidic) is a synthetic peptide modeled on a component of temple viper venom. The proposed mechanism is nicotinic acetylcholine receptor antagonism in the dermis, producing reduced expression lines. The peer-reviewed clinical base is sponsor-published and limited.
Syn-Coll (palmitoyl tripeptide-5) is positioned as a TGF-beta mimetic, with proposed collagen-synthesis upregulation. The published clinical evidence is consistent with the broader matrikine peptide class: small effect sizes, short trial durations.
Dipeptide-2 and Decapeptide-12 target specific cosmetic indications. Dipeptide-2 is marketed for periorbital edema. Decapeptide-12 is studied for hyperpigmentation through tyrosinase inhibition. Both have sponsor-funded clinical data of moderate size.
Epitalon crosses categories. It is an oral or injectable tetrapeptide developed by Vladimir Khavinson's group, marketed for longevity through telomerase activation in cell models. Some online discussion places it in skin anti-aging based on rodent data showing increased lifespan and reduced age-related morphological markers. Human cosmetic-endpoint trials are almost entirely absent. Treat skin anti-aging claims about Epitalon as extrapolation, not as topical-trial-confirmed.
What cosmetic peptides actually deliver
The honest summary: topical cosmetic peptides produce measurable but modest improvements in wrinkle depth, skin elasticity, and barrier function in controlled trials of 4 to 12 weeks. Effect sizes are smaller than tretinoin, retinoids, or in-clinic procedures. Combined formulations may have additive effects, but the additive trial data is limited.
Regulatory note. Cosmetic peptide products are not approved by the FDA for the treatment of disease. Claims that a topical peptide "reverses aging" or "restores youth" exceed what cosmetic regulation allows and exceed what the trial base supports. PeptScope reports the trial outcomes as published.
How peptides compare to the gold-standard topicals
The most evidence-backed anti-aging topicals are prescription retinoids (tretinoin, tazarotene) and over-the-counter retinol. Multi-year placebo-controlled trials document reductions in photoaging, fine lines, and pigmentation that exceed the effect sizes reported in cosmetic peptide trials. Peptides are best read as adjunct ingredients in a broader regimen, not as standalone replacements for retinoids, sunscreen, or in-clinic procedures. Vitamin C, niacinamide, and alpha-hydroxy acids also have stronger comparative trial data than most marketed peptide complexes.
Stacking and formulation realities. A finished serum often combines three to six peptides plus humectants, antioxidants, and barrier-support ingredients. The trial data for individual peptides does not transfer cleanly to the multi-ingredient product. Concentration matters. So does formulation pH and the carrier system. A 5 percent argireline serum at the correct pH is not the same product as a 0.5 percent argireline serum marketed under the same ingredient name. Reader screening of cosmetic peptide claims should account for concentration, vehicle, and trial duration before weighting effect-size claims.